Royalty Pharma 2024年第四季度调整后每股收益$1.16超出$1.05的预期，销售额$5.94亿未达到$6.78亿的预期

财报速递2025-02-11
Royalty Pharma（纳斯达克股票代码：RPRX）报告季度每股收益为$1.16，超过分析师一致预期的$1.05，增幅为10.48%。与去年同期每股收益$1.15相比，这增长了0.87%。公司报告季度销售额为$5.94亿，未达到分析师一致预期的$6.78亿，相差12.50%。与去年同期销售额$5.96亿相比，下降了0.34%。

以上内容来自Benzinga Earnings专栏，原文如下：

Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $1.16 per share which beat the analyst consensus estimate of $1.05 by 10.48 percent. This is a 0.87 percent increase over earnings of $1.15 per share from the same period last year. The company reported quarterly sales of $594.00 million which missed the analyst consensus estimate of $678.89 million by 12.50 percent. This is a 0.34 percent decrease over sales of $596.00 million the same period last year.

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白
发表看法